Progressive Supranuclear Palsy (PSP)

🧠 Standard of Care & Symptoms

Progressive Supranuclear Palsy (PSP) is a rare, progressive neurodegenerative disorder classified as an "atypical parkinsonian syndrome" or "Parkinson-plus" syndrome.

• Presentation: Supranuclear gaze deficits, postural instability, and bulbar symptoms.
  • Vertical Supranuclear Gaze Palsy: The hallmark clinical feature. Selective difficulty looking up or down (especially downward gaze). This causes patients to trip over low obstacles or spill food (referred to as the "dirty tie sign"). Reflexive eye movements (via the vestibulo-ocular reflex) remain intact.
  • Postural Instability & Falls: Develops early in the disease course (often within the first year). Falls are characteristically **backward** due to axial rigidity and loss of postural reflexes.
  • Rigidity & Bradykinesia: Symmetric muscle stiffness, primarily affecting axial (trunk) muscles rather than limbs, with slow movements and a blank facial expression (masked facies).
  • Pseudobulbar Palsy: Severe dysarthria (slurred, growling speech) and dysphagia (difficulty swallowing), increasing the risk of aspiration pneumonia.
• Atypical Features: Unlike Parkinson's Disease, patients with PSP display symmetric symptoms at onset, lack a resting tremor, and show poor or absent response to levodopa.

🧬 Diagnostics & 4R Tau Pathology

Diagnosis is based on Movement Disorder Society (MDS) criteria. High-resolution sagittal brain MRI is critical to exclude vascular disease or normal pressure hydrocephalus.

• Brain MRI (Sagittal Views): Demonstrates prominent **midbrain atrophy** with relative preservation of the pons. This produces the pathognomonic **"hummingbird sign"** (or "penguin sign"), where the sagittal profile of the midbrain resembles a hummingbird's beak.
• Neuropsychological Testing: Reveals subcortical dementia, characterized by apathy, slowed cognitive processing, and executive dysfunction.

Molecular Pathology & 4-Repeat (4R) Tauopathy

The neurodegeneration in PSP is driven by the pathological aggregation of specific microtubule-associated proteins:

• 4-Repeat (4R) Tau Accumulation: PSP is a primary **4R tauopathy**. Microtubule-associated tau proteins contain either 3 or 4 microtubule-binding repeats (3R or 4R). In PSP, an abnormal ratio leads to the accumulation of hyperphosphorylated 4R tau isoforms within neurons and glial cells.
• Pathological Glial Markers: Hyperphosphorylated tau aggregates into globose neurofibrillary tangles in neurons. A key diagnostic feature is the presence of **tufted astrocytes** and coiled bodies in oligodendrocytes.
• Subcortical Targeting: Neurodegeneration selectively destroys synapses and cells within the subthalamic nucleus, substantia nigra, globus pallidus, and oculomotor nuclei, explaining the motor and gaze symptoms.

💊 Atypical Parkinsonism & Fall Prevention

There is currently no disease-modifying therapy for PSP. Treatment focuses on fall prevention, preserving communication and swallowing, and managing rigidity.

Symptomatic Pharmacotherapy

• Levodopa Trial: A standard trial of carbidopa-levodopa (up to 1000 mg/day) is initiated. While up to 30% of patients show a mild, transient response, long-term efficacy is poor.
• Botulinum Toxin Injections: Directed to the orbicularis oculi muscles to manage severe blepharospasm (involuntary eyelid closure) or apraxia of lid opening.

Physical Therapy & Fall Prevention

• Weighted Walkers: Crucial to prevent backward falls. Standard rolling walkers can roll away and worsen instability; heavily weighted, rear-wheeled walkers are recommended.
• Specialized Lenses: Prism glasses can help redirect the visual field downward, compensating for the loss of downward vertical gaze.

Bulbar & Nutrition Management

• Dysphagia Care: Routine swallowing assessments are mandatory. Thickeners for liquids and head-positioning maneuvers help prevent aspiration. In advanced stages, a gastrostomy (PEG) tube is discussed to maintain nutrition.

🔬 Active Clinical Trials

Clinical trials are currently evaluating anti-tau monoclonal antibodies designed to clear hyperphosphorylated tau, microtubule stabilizers, and digital gait-tracking platforms.

🗺️ Next Steps After Diagnosis

If you or a loved one have recently been diagnosed with PSP, follow these clinical steps:

1. Confirm Midbrain Atrophy: Verify brain MRI shows the classic "hummingbird sign" to support the diagnosis of PSP over Parkinson's disease.
2. Initiate a Levodopa Trial: Discuss a trial of Carbidopa-Levodopa with your neurologist; though benefit is often minimal, it should be tested.
3. Obtain a Weighted Walker: Order a specialized weighted or rear-wheeled walker early to prevent dangerous backward falls.
4. Schedule a Swallowing Evaluation: Get a baseline swallowing test from a speech therapist to manage choking risks.

❓ Patient FAQ

Q: Why does my loved one fall backward so often? How is this different from Parkinson's?
A: In Parkinson's Disease, patients tend to bend forward and take fast, shuffling steps, causing them to fall forward. In Progressive Supranuclear Palsy (PSP), the stiffness (rigidity) primarily affects the neck and spine (axial rigidity), causing the patient to stand extremely straight or even tilt slightly backward. Combined with a loss of postural reflexes and difficulty looking down, they are unable to see obstacles or adjust their balance, leading to sudden, unprotected backward falls.

Q: Why doesn't standard Parkinson's medication (Levodopa) work for PSP?
A: In Parkinson's Disease, the main problem is a loss of dopamine-producing cells in the substantia nigra, but the post-synaptic receptors that receive dopamine remain healthy. Therefore, giving Levodopa (which converts to dopamine) works very well. In PSP, the toxic tau protein aggregates destroy not only the dopamine-producing cells but also the post-synaptic receptors (dopamine D2 receptors) in the globus pallidus and subthalamic nucleus. Because the target receptors are destroyed, Levodopa has little to no effect.